Prazepam is indicated for the short-term treatment of anxiety. After short-term therapy, the dose is usually gradually tapered-off to reduce or avoid any withdrawalorrebound effects.[5][6]Desmethyldiazepam, an active metabolite, has a very long half-life of 29 to 224 hours, which contributes to the therapeutic effects of prazepam.[7][8]
Side effects of prazepam are less profound than with other benzodiazepines.[9] Excessive drowsiness and with longer-term use, drug dependence, are the most common side effects of prazepam.[10][11] Side effects such as fatigue or "feeling spacey" can also occur but less commonly than with other benzodiazepines. Other side effects include feebleness, clumsiness or lethargy, clouded thinking and mental slowness.[12][13][14]
Tolerance and dependence can develop with long-term use of prazepam, and upon cessation or reduction in dosage, then a benzodiazepine withdrawal syndrome may occur with symptoms such as tremulousness, dysphoria, psychomotor agitation, tachycardia and sweating. In severe cases, hallucinations, psychosis and seizures can occur. Withdrawal-related psychosis is generally unresponsive to antipsychotic mediations. The risk and severity of the withdrawal syndrome increases the higher the dose and the longer prazepam is taken for.[15] Tolerance, dependence and withdrawal problems may be less severe than with other benzodiazepines, such as diazepam.[16] It may be because tolerance is slower to develop with prazepam than with other benzodiazepines.[17] Abrupt or over-rapid discontinuation of prazepam after long-term use, even at low dosage, may result in a protracted withdrawal syndrome.[18]
Benzodiazepines can induce serious problems of addiction, which is one of the main reasons for their use being restricted to short-term use. A survey in Senegal found that the majority of doctors believed that their training in this area was generally poor. It was recommended that national authorities take urgent action regarding the rational use of benzodiazepines. Almost one-fifth of doctors ignored prescription guidelines regarding short-term use of benzodiazepines, and almost three-quarters of doctors regarded their training and knowledge of benzodiazepines to be inadequate. More training regarding benzodiazepines has been recommended for doctors.[19][20]
Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, alcohol or drug-dependent individuals and individuals with comorbidpsychiatric disorders.[21]
Prazepam exerts its therapeutic effects primarily via modulating the benzodiazepine receptor which in turn enhances GABA function in the brain.[22] Prazepam like other benzodiazepines has anticonvulsant properties, but its anticonvulsant properties are not as potent as other benzodiazepines when tested in animal studies.[23][24][25][26]
Prazepam is metabolised into descyclopropylmethylprazepam (also known as desmethyldiazepam) and 3-hydroxyprazepam which is further metabolised into oxazepam.[27][28][29][30][31] Prazepam is a prodrug for descyclopropylmethylprazepam/desmethyldiazepam (also known as norprazepam or nordazepam) which is responsible for most of the therapeutic activity of prazepam rather than prazepam itself.[15][22][32][33]
Prazepam may interact with cimetidine.[34]Alcohol in combination with prazepam increases the adverse effects, particularly performance impairing side effects and drowsiness.[35]
The symptoms of an overdose of prazepam include sleepiness, agitation and ataxia. Hypotonia may also occur in severe cases. Overdoses in children typically result in more severe symptoms of overdose.[36]
Prazepam like other benzodiazepines has abuse potential and can be habit forming. However, its abuse potential may be lower than other benzodiazepines because it has a slow onset of action.[15][37]
^US Patent 3192199 – Process for the production of I-CYCLO- ALKYL derivatives of I,X-BENZODIAZEPINE
^Shader RI, Greenblatt DJ (1979). "Benzodiazepines: some aspects of their clinical pharmacology". Ciba Foundation Symposium. Novartis Foundation Symposia. 1979 (74): 141–155. doi:10.1002/9780470720578.ch9. ISBN9780470720578. PMID45081.
^Jacqmin P, Ansseau M (1988). "Comparison of sublingual and oral prazepam in normal subjects. II. Pharmacokinetic and pharmacodynamic data". Neuropsychobiology. 19 (4): 186–191. doi:10.1159/000118458. PMID2854609.
^Rickels K, Sablosky L, Silverman H, Case WG, Rial W, Mirman M, Gottlieb S (1977). "Prazepam in anxiety: a controlled clinical trial". Comprehensive Psychiatry. 18 (3): 239–249. doi:10.1016/0010-440X(77)90018-9. PMID858240.
^Ansseau M, Von Frenckell R (1991). "[Value of prazepam drops in the brief treatment of anxiety disorders]" [Value of prazepam drops in the brief treatment of anxiety disorders]. L'Encephale (in French). 17 (4): 291–294. PMID1959497.
^Breimer DD, Jochemsen R, von Albert HH (1980). "Pharmacokinetics of benzodiazepines. Short-acting versus long-acting". Arzneimittel-Forschung. 30 (5a): 875–881. PMID6106488.
^Allen MD, Greenblatt DJ, Harmatz JS, Shader RI (August 1980). "Desmethyldiazepam kinetics in the elderly after oral prazepam". Clinical Pharmacology and Therapeutics. 28 (2): 196–202. doi:10.1038/clpt.1980.150. PMID6772370. S2CID7514074.
^Greenblatt DJ, Harmatz JS, Dorsey C, Shader RI (September 1988). "Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo". Clinical Pharmacology and Therapeutics. 44 (3): 326–334. doi:10.1038/clpt.1988.158. PMID3138056. S2CID20150379.
^Danion JM, Brion S, Escande M, Ropert R, Sacquepee L, Singer L, Scotto JC (1984). "[Treatment of anxiety with prazepam, 40 mg. A controlled study versus lorazepam]" [Treatment of anxiety with prazepam, 40 mg. A controlled study versus lorazepam]. L'Encephale (in French). 10 (3): 135–138. PMID6389091.
^Dièye AM, Sy B, Diarra M, Faye B (March 2004). "[Prescription and use of benzodiazepins in Saint-Louis in Senegal: patient survey]" [Prescription and use of benzodiazepins in Saint-Louis in Senegal: patient survey]. Annales Pharmaceutiques Françaises (in French). 62 (2): 133–137. doi:10.1016/S0003-4509(04)94292-7. PMID15107731.
^Shader RI, Pary RJ, Harmatz JS, Allison S, Locniskar A, Greenblatt DJ (October 1984). "Plasma concentrations and clinical effects after single oral doses of prazepam, clorazepate, and diazepam". The Journal of Clinical Psychiatry. 45 (10): 411–413. PMID6148339.
^Ansseau M, von Frenckell R, Jacqmin P (1987). "Comparison of sublingual and oral prazepam in normal subjects. I. Clinical data". Neuropsychobiology. 18 (2): 77–82. doi:10.1159/000118397. hdl:2268/249065. PMID3330182.
^Chabannes JP, Lemoine P (1990). "[Prazepam drops versus 10 mg prazepam tablets in anxious patients in ambulatory care]" [Prazepam drops versus 10 mg prazepam tablets in anxious patients in ambulatory care]. Therapie (in French). 45 (6): 467–470. PMID2080484.
^Dorman T (1983). "A multi-centre comparison of prazepam and diazepam in the treatment of anxiety". Pharmatherapeutica. 3 (6): 433–440. PMID6353434.
^Saletu M, Saletu B, Grünberger J, Mader R, Karobath M (1983). "Clinical symptomatology and computer analyzed EEG before, during and after anxiolytic therapy of alcohol withdrawal patients". Neuropsychobiology. 9 (2–3): 119–134. doi:10.1159/000117949. PMID6353268.
^Soyka M, Lehle R, Hippius H (September 1994). "[Exacerbation of an affective psychosis after terminating a decade of benzodiazepine treatment. Which therapeutic procedure is sensible?]" [Exacerbation of an affective psychosis after terminating a decade of benzodiazepine treatment. Which therapeutic procedure is sensible?]. Der Nervenarzt (in German). 65 (9): 628–632. PMID7991010.
^Dièye AM, Sylla M, Ndiaye A, Ndiaye M, Sy GY, Faye B (June 2006). "Benzodiazepines prescription in Dakar: a study about prescribing habits and knowledge in general practitioners, neurologists and psychiatrists". Fundamental & Clinical Pharmacology. 20 (3): 235–238. doi:10.1111/j.1472-8206.2006.00400.x. PMID16671957. S2CID20619323.
^Dièye AM, Sy AN, Sy GY, Diallo AA, Diarra M, Ndiaye M, Faye B (2007).『Prescription des benzodiazépines par les médecins généralistes du privé à Dakar : Enquête sur les connaissances et les attitudes』[Prescription of benzodiazepines by general practitioners in the private sector of Dakar: survey on knowledge and attitudes]. Therapie (in French). 62 (2): 163–168. doi:10.2515/therapie:2007018. PMID17582318.
^Authier N, Balayssac D, Sautereau M, Zangarelli A, Courty P, Somogyi AA, et al. (November 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". Annales Pharmaceutiques Françaises. 67 (6): 408–413. doi:10.1016/j.pharma.2009.07.001. PMID19900604.
^ abQuast U (May 1981). "[Molecular mechanism of action of benzodiazepines]" [Molecular mechanism of action of benzodiazepines]. Fortschritte der Medizin (in German). 99 (20): 788–794. PMID6114911.
^De Sarro G, Gitto R, Rizzo M, Zappia M, De Sarro A (September 1996). "1,4-Benzodiazepine derivatives as anticonvulsant agents in DBA/2 mice". General Pharmacology. 27 (6): 935–941. doi:10.1016/0306-3623(95)02147-7. PMID8909973.
^De Sarro G, Chimirri A, Zappala M, Guisti P, Lipartiti M, De Sarro A (October 1996). "Azirino[1, 2-d][1, 4]benzodiazepine derivatives and related 1,4-benzodiazepines as anticonvulsant agents in DBA/2 mice". General Pharmacology. 27 (7): 1155–1162. doi:10.1016/S0306-3623(96)00049-3. PMID8981061.
^De Sarro G, Chimirri A, McKernan R, Quirk K, Giusti P, De Sarro A (September 1997). "Anticonvulsant activity of azirino[1,2-d][1,4]benzodiazepines and related 1,4-benzodiazepines in mice". Pharmacology, Biochemistry, and Behavior. 58 (1): 281–289. doi:10.1016/S0091-3057(96)00565-5. PMID9264104. S2CID24492818.
^Fukinaga M, Ishizawa K, Kamei C (November 1998). "Anticonvulsant properties of 1,4-benzodiazepine derivatives in amygdaloid-kindled seizures and their chemical structure-related anticonvulsant action". Pharmacology. 57 (5): 233–241. doi:10.1159/000028247. PMID9742288. S2CID25773207.
^Viau JP, Epps JE, Di Carlo J (September 1973). "Prazepam metabolism after chronic administration to humans". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 3 (9): 581–587. doi:10.3109/00498257309151546. PMID4763144.
^Valavani P, Atta-Politou J, Panderi I (April 2005). "Development and validation of a liquid chromatographic/electrospray ionization mass spectrometric method for the quantitation of prazepam and its main metabolites in human plasma". Journal of Mass Spectrometry. 40 (4): 516–526. Bibcode:2005JMSp...40..516V. doi:10.1002/jms.824. PMID15712230.
^Nau H, Liddiard C, Jesdinsky D, Wittfoht W (September 1978). "Quantitative analysis of prazepam and its metabolites by electron capture gas chromatography and selected ion monitoring. Application to diaplacetal passage and fetal hepatic metabolism in early human pregnancy". Journal of Chromatography. 146 (2): 227–239. doi:10.1016/S0378-4347(00)81889-7. PMID701422.
^Kölle EU (June 1981). "[Pharmacokinetics of oral prazepam]" [Pharmacokinetics of oral prazepam]. Fortschritte der Medizin (in German). 99 (22): 874–879. PMID6790396.
^Ruffalo RL, Thompson JF, Segal J (September 1981). "Cimetidine-benzodiazepine drug interaction". American Journal of Hospital Pharmacy. 38 (9): 1365–1366. PMID6116430.
^Girre C, Hirschhorn M, Bertaux L, Palombo S, Fournier PE (1991). "Comparison of performance of healthy volunteers given prazepam alone or combined with ethanol. Relation to drug plasma concentrations". International Clinical Psychopharmacology. 6 (4): 227–238. doi:10.1097/00004850-199100640-00004. PMID1816280.
^Pulce C, Mollon P, Pham E, Frantz P, Descotes J (April 1992). "Acute poisonings with ethyle loflazepate, flunitrazepam, prazepam and triazolam in children". Veterinary and Human Toxicology. 34 (2): 141–143. PMID1354907.
^Hakuba A, Matysiakiewicz J (1986). "[The habit-forming effect of prazepam]" [The habit-forming effect of prazepam]. Psychiatria Polska (in Polish). 20 (3): 232–234. PMID3797537.
^Fox KA, Guerriero FJ (July 1978). "Effect of benzodiazepines on age of vaginal perforation and first estrus in mice". Research Communications in Chemical Pathology and Pharmacology. 21 (1): 181–184. PMID28555.
^Guerriero FJ, Fox KA (April 1976). "Benzodiazepines and reproduction of swiss-webster mice". Research Communications in Chemical Pathology and Pharmacology. 13 (4): 601–610. PMID4863.
^Guerriero FJ, Fox KA (May 1975). "Benzodiazepine-induced suppression of estrous cycles in C57BL/6J mice". Research Communications in Chemical Pathology and Pharmacology. 11 (1): 155–158. PMID239442.
